Join our daily newsletter At The Bell to receive exclusive market insights
- Bionomics (BNO) has received Foreign Investment Review Board (FIRB) approval for Aperion Investment Group to nab a 52 per cent stake in the company
- In June, the clinical-stage biopharmaceutical company entered a subscription agreement with Aperion
- Under this agreement, Aperion will purchase over $5.4 million worth of shares
- Aperion also agreed to underwrite Bionomics’ capital raises within a 15 month period from the shareholders meeting
- Bionomics can raise up to $15 million within this period at a minimum issue price of six cents per share
- The funds will go towards the BNC210 phase two clinical trial for the treatment of post-traumatic stress disorder
- On market close, Bionomics is up 2.86 per cent and is trading for 18 cents per share
Bionomics (BNO) has received Foreign Investment Review Board (FIRB) approval for Aperion Investment Group to nab a 52 per cent stake in the company.
Aperion is the family office of entrepreneur and founder Christian Angermayer. It focuses on financial services, deep-tech, life sciences, media and entertainment, and real estate.
Over the past few years, the family business made significant investments in Europe and U.S.-based biotech companies. The main focus of these investments was for the development of novel treatments for mental health disorders like treatment-resistant depression, anxiety and Post Traumatic Stress Disorder- diseases with a high unmet medical need.
In June, the clinical-stage biopharmaceutical company entered into a subscription agreement with Aperion.
Under this agreement, Aperion will purchase over $5.4 million worth of shares. However, the deal needed the FIRB and shareholder approval.
Aperion also agreed to underwrite further capital raises by Bionomics within a 15-month period from the shareholder meeting. The capital raises to be underwritten by Aperion can not exceed $15 million and the minimum issue price must be no less than six cents per share.
Today, the FIRB has given the green light to the companies on this investment. Shareholder approval was granted on the general meeting on August 26.
“This is great news which will ensure that the company has significant funds to progress the second BNC210 phase two clinical trial for the treatment of post-traumatic stress disorder projected for mid-2021,” Bionomics Executive Chairman Dr De Souza said.
On market close, Bionomics is up 2.86 per cent and is trading for 18 cents per share.
